Tumor-selective transgene expression in vivo mediated by an E2F- responsive adenoviral vector

Nature Medicine

Volumn 3, Issue 10, 1997, Pages 1145-1149

  Parr, Michael J ^a   Manome, Yoshinobu ^a   Tanaka, Toshihide ^a   Wen, Patrick ^a   Kufe, Donald W ^a   Kaelin Jr , William G ^a   Fine, Howard A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR E2F; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXICITY TEST; EXPRESSION VECTOR; GENE EXPRESSION; GLIOMA; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSGENE; VIRUS RECOMBINANT;

ADENOVIRUSES, HUMAN; ANIMALS; ASTROCYTOMA; BETA-GALACTOSIDASE; BRAIN; BRAIN NEOPLASMS; CARRIER PROTEINS; CELL CYCLE; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; GENE THERAPY; GENETIC VECTORS; GLIOMA; PROMOTER REGIONS (GENETICS); RATS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTION FACTOR DP1; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0030860227     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1097-1145     Document Type: Article

References (24)

1. Weinberg, R.A. The retinoblastoma protein and cell cycle control. Cell 81, 323-330 (1995).
2. He, J. et al. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res. 54, 5804-5807 (1994).
3. Ueki, K. et al. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 56, 150-153 (1996).
4. Jen, J. et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 54, 6353-6358 (1994).
5. Schmidt, E.E., Ichimura, K., Reifenberger, C. & Collins, V.P. CDKN2/p16/MTSI/ gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 54, 6321-6324 (1994).
6. Adams, P.D. & Kaelin, W.G. Transcriptional control by E2F. Semin. Cancer Biol. 6, 99-108 (1995).
7. Sellers, W.R., Neuman, E. & Kaelin, W.G. The retinobtastoma protein contains a potent transrepression domain which induces a cell-cycle block when bound to DNA. Proc. Natl. Acad. Sci. USA 92, 11544-11548 (1995).
8. Tevosian, S.G., Paulson, K.E., Bronson, R. & Yee, A.S. Expression of the E2F-1/DP-1 transcription factor in murine development. Cell Growth Differ. 7, 43-52 (1996).
9. Kaelin, W.G. et al. Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell 70, 351-364 (1992).
10. Neuman, E., Flemington, E.K., Sellers, W.R. & Kaelin, W.G. Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter. Mol. Cell. Biol. 14, 6607-6615 (1994).
11. Johnson, D.G., Kiyoshi, O. & Nevins, J.R. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev. 8, 1514-1525 (1994).
12. Hsiao, K.-M., McMahon, S.L. & Famham, P. Multiple DNA elements are required for the growth regulation of the mouse E2F1 promoter. Genes Dev. 8, 1526-1537 (1994).
13. Johnson, D.G. Regulation of E2F-1 gene expression by p130(Rb2) and D-type cyclin kinase activity. Oncogene 11, 1685-1692 (1995).
14. McGrory, W.J., Bautista, D.S. & Graham, F.L. A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5. Virology 163, 614-617 (1988).
15. Ghosh-Choudhury, G., Haj-Ahmad, Y., Brinkley, P., Rudy, J. & Graham, F.L. Human adenovirus cloning vectors based on infectious bacterial plasmids. Gene 50, 161-171 (1986).
16. Culver, K.W. et al. In vivo gene transfer with retroviral-vector producer cells for treatment of experimental brain tumors. Science 256, 1550-1552 (1992).
17. Ram, Z., Culver, K.W., Walbridge, S., Blaese, R.M. & Oldfield, E.H. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53, 3475-3485 (1993).
18. Fine, H.A. Prospects for gene therapy as an innovative approach to malignant gliomas. Perspect. Neurol. Surg. 5, 115-127 (1994).
19. Manome, Y. et al. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nature Med. 2, 567-573 (1996).
20. Goodman, J. et al. Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir; pathologic, radiographic, and molecular studies. Hum. Gene Ther. 7, 1241-50 (1996).
21. Fults, D., Brockmeyer, D., Tullous, M.W., Pedone, C.A. & Cawthone, R.M. p53 mutation and loss of heterozygosity on chromosome 17 and 10 during human astrocytoma progression. Cancer Res. 52, 674-679 (1992).
22. Dong, Y. et al. In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Hum. Gene Ther. 7, 713-720 (1996).
23. Graham, F.L., Smiley, J., Russel, W.C. & Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-72 (1977).
24. Kobayashi, N., Allen, N., Clendenon, N.R. & Ko, L.-W. An improved rat brain-tumor model. J. Neurosurg. 53, 808-815 (1980).